Edition:
United States

Chembio Diagnostics Inc (CEMI.OQ)

CEMI.OQ on NASDAQ Stock Exchange Capital Market

7.30USD
23 Feb 2018
Change (% chg)

$0.15 (+2.10%)
Prev Close
$7.15
Open
$7.20
Day's High
$7.30
Day's Low
$7.15
Volume
42,514
Avg. Vol
6,273
52-wk High
$9.20
52-wk Low
$5.05

Chart for

About

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies,... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $89.93
Shares Outstanding(Mil.): 12.32
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-Chembio Diagnostics Announces Proposed Public Offering Of Common Stock

* CHEMBIO DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 08 2018

BRIEF-Chembio Diagnostics Announces Major New Tender Win And Certain Preliminary 2017 Financial Results

* CHEMBIO DIAGNOSTICS ANNOUNCES MAJOR NEW TENDER WIN AND CERTAIN PRELIMINARY 2017 FINANCIAL RESULTS

Feb 08 2018

BRIEF-Chembio Diagnostics Appoints Neil Goldman As CFO

* CHEMBIO DIAGNOSTICS ANNOUNCES APPOINTMENT OF NEIL A. GOLDMAN AS CHIEF FINANCIAL OFFICER

Dec 20 2017

BRIEF-Chembio Diagnostics And Astrazeneca Collaborates To Develop Point-Of-Care Diagnostic Test

* CHEMBIO DIAGNOSTICS AND ASTRAZENECA ENTER A COLLABORATION TO DEVELOP POINT-OF-CARE DIAGNOSTIC TEST

Dec 19 2017

BRIEF-Chembio receives $8.5 mln commitment from Bio-Manguinhos to purchase components for production of dpp Assays in Brazil during 2018

* CHEMBIO RECEIVES $8.5 MILLION COMMITMENT FROM BIO-MANGUINHOS TO PURCHASE COMPONENTS FOR PRODUCTION OF DPP® ASSAYS IN BRAZIL DURING 2018

Dec 05 2017

BRIEF-Chembio Diagnostics Awarded UNICEF Contract

* CHEMBIO DIAGNOSTICS AWARDED UNICEF CONTRACT TO SUPPLY POINT-OF-CARE DPP® ZIKA ASSAYS AND DPP® MICRO READERS

Nov 28 2017

BRIEF-Chembio Diagnostics posts Q3 loss of $0.05 per share

* Chembio diagnostics reports third quarter 2017 financial results

Nov 08 2017

BRIEF-Chembio Diagnostics CEO has returned to work after a medical leave of absence​

* Chembio Diagnostics Inc - president and CEO ‍John Sperzel has returned to work following a medical leave of absence​ Source text for Eikon: Further company coverage:

Oct 02 2017

BRIEF-Chembio Diagnostics receives FDA emergency use authorization for the first rapid Zika Igm test

* Chembio Diagnostics receives FDA emergency use authorization for the first rapid Zika Igm test Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Sep 28 2017

Competitors

Earnings vs. Estimates